The experimental treatment, TERN-601, is part of the second generation of weight-loss drugs, which aim to offer a more convenient alternative to injections, under development by companies including Pfizer and Roche.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/ydlopIM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment